TY - JOUR

T1 - Reproducibility of the CO rebreathing technique with a lower CO dose and a shorter rebreathing duration at sea level and at 2320 m of altitude

AU - Oberholzer, Laura

AU - Bonne, Thomas Christian

AU - Breenfeldt Andersen, Andreas

AU - Bejder, Jacob

AU - Højgaard Christensen, Regitse

AU - Nordsborg, Nikolai Baastrup

AU - Lundby, Carsten

N1 - CURIS 2020 NEXS 314

PY - 2020

Y1 - 2020

N2 - Total hemoglobin mass (Hbmass) is routinely assessed in studies by the carbon monoxide (CO) rebreathing. Its clinical application is often hindered due to the consequent rise in carboxyhemoglobin (%HbCO) and the concern of CO toxicity. We tested the reproducibility of the CO rebreathing with a CO dose of 0.5 mL/kg body mass (CO0.5) compared to 1.5 mL/kg (CO1.5) and when shortening the CO rebreathing protocol. Therefore, CO rebreathing was performed 1×/day in eight healthy individuals on four consecutive days. On each day, either CO0.5 (CO0.5-1 and CO0.5-2) or CO1.5 (CO1.5-1 and CO1.5-2) was administered. Venous blood samples to determine %HbCO and quantify Hbmass were obtained prior to, and at 6 (T6), 8 (T8) and 10 min (T10) of CO rebreathing. This protocol was tested at sea level and at 2320 m to investigate the altitude-related measurement error. At sea level, the mean difference (95% limits of agreement) in Hbmass between CO0.5-1 and CO0.5-2 was 26 g (–26; 79 g) and between CO1.5-1 and CO1.5-2, it was 17 g (–18; 52 g). The respective typical error (TE) corresponded to 2.4% (CO0.5) and 1.5% (CO1.5), while it was 6.5% and 3.0% at 2320 m. With CO0.5, shortening the CO rebreathing resulted in a TE for Hbmass of 4.4% (T8 vs. T10) and 14.1% (T6 vs T10) and with CO1.5, TE was 1.6% and 5.8%. In conclusion, the CO dose and rebreathing time for the CO rebreathing procedure can be decreased at the cost of a measurement error ranging from 1.5-14.1%.

AB - Total hemoglobin mass (Hbmass) is routinely assessed in studies by the carbon monoxide (CO) rebreathing. Its clinical application is often hindered due to the consequent rise in carboxyhemoglobin (%HbCO) and the concern of CO toxicity. We tested the reproducibility of the CO rebreathing with a CO dose of 0.5 mL/kg body mass (CO0.5) compared to 1.5 mL/kg (CO1.5) and when shortening the CO rebreathing protocol. Therefore, CO rebreathing was performed 1×/day in eight healthy individuals on four consecutive days. On each day, either CO0.5 (CO0.5-1 and CO0.5-2) or CO1.5 (CO1.5-1 and CO1.5-2) was administered. Venous blood samples to determine %HbCO and quantify Hbmass were obtained prior to, and at 6 (T6), 8 (T8) and 10 min (T10) of CO rebreathing. This protocol was tested at sea level and at 2320 m to investigate the altitude-related measurement error. At sea level, the mean difference (95% limits of agreement) in Hbmass between CO0.5-1 and CO0.5-2 was 26 g (–26; 79 g) and between CO1.5-1 and CO1.5-2, it was 17 g (–18; 52 g). The respective typical error (TE) corresponded to 2.4% (CO0.5) and 1.5% (CO1.5), while it was 6.5% and 3.0% at 2320 m. With CO0.5, shortening the CO rebreathing resulted in a TE for Hbmass of 4.4% (T8 vs. T10) and 14.1% (T6 vs T10) and with CO1.5, TE was 1.6% and 5.8%. In conclusion, the CO dose and rebreathing time for the CO rebreathing procedure can be decreased at the cost of a measurement error ranging from 1.5-14.1%.

KW - Anemias

KW - Blood and cardiovascular physiology

KW - Blood gases

KW - Hematology

KW - Method selection and validation

UR - http://www.scopus.com/inward/record.url?scp=85091197432&partnerID=8YFLogxK

U2 - 10.1080/00365513.2020.1818282

DO - 10.1080/00365513.2020.1818282

M3 - Journal article

C2 - 32955368

AN - SCOPUS:85091197432

VL - 80

SP - 590

EP - 599

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

SN - 0036-5513

IS - 7

ER -